Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Molecular Basis Of Minimal Residual Disease In Subtypes Of Pediatric B Cell Acute Lymphoblastic Leukemia

Jitsuda Sitthi-Amorn, MD, Betty Herrington, MD, Gail Megason, MD, Jeanette Pullen, MD, Catherine Gordon, MD, Shirley Hogan, Pharm.D, Tejaswi Koganti, MS, Chindo Hick, PhD

Blood (2013) 122 (21): 1390.

https://doi.org/10.1182/blood.V122.21.1390.1390

Published: 2013

Journal Articles

Delayed Intensification (DI) Enhances Event-Free Survival (EFS) of Children with B-Precursor Acute Lymphoblastic Leukemia (ALL) Who Received Intensification Therapy with Six Courses of Intravenous Methotrexate (MTX): POG 9904/9905: A Childrens Oncology Group Study (COG).

Naomi Winick, MD, Paul L. Martin, MD, PhD, Meenakshi Devidas, PhD, Jonathan Shuster, PhD, Michael J. Borowitz, MD, PhD, Paul Bowman, MD, Eric Larsen, MD, Jeanette Pullen, MD, Stephen P. Hunger, MD, William L. Carroll, MD, Bruce M. Camitta, MD

Blood (2007) 110 (11): 583.

https://doi.org/10.1182/blood.V110.11.583.583

Published: 2007

Journal Articles

Prospective Analysis of TEL and MLL Gene Rearrangements in Childhood Acute Lymphoblastic Leukemia: A Children’s Oncology Group Study.

Jeffrey Rubnitz, MD, PhD, David Wichlan, MS, Meenakshi Devidas, PhD, Jonathan Shuster, PhD, Joanne Kurtzberg, MD, Beverly Bell, MD, Stephen Hunger, MD, Allen Chauvenet, MD, Ching-Hon Pui, MD, Bruce Camitta, MD, Jeanette Pullen, MD

Blood (2006) 108 (11): 218.

https://doi.org/10.1182/blood.V108.11.218.218

Published: 2006

Journal Articles

Prognostic Significance of Minimal Residual Disease (MRD) in Childhood B-Precursor ALL and Its Relation to Other Risk Factors. A Children’s Oncology Group (COG) Study.

Michael J. Borowitz, MD, PhD, Meenakshi Devidas, PhD, W. Paul Bowman, MD, William L. Carroll, MD, I.-Ming Chen, MD, Richard Harvey, PhD, Stephen Hunger, MD, Paul L. Martin, Jeanette Pullen, MD, David Viswanatha, MD, Cheryl L. Willman, MD, Naomi Winick, MD, Bruce Camitta, MD

Blood (2006) 108 (11): 219.

https://doi.org/10.1182/blood.V108.11.219.219

Published: 2006

Journal Articles

A Report of the Event Free Survival (EFS) for Children with Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia (ALL) Treated on Pediatric Oncology Group (POG) Protocol 9605.

Beverly A. Bell, MD, Sharon B. Abish, MD, Allen Chauvenet, MD, Joanne Kurtzberg, MD, Jeanette Pullen, MD, Meenakshi Devidas, PhD, Jonathan Shuster, PhD, Bruce M. Camitta, MD

Blood (2005) 106 (11): 875.

https://doi.org/10.1182/blood.V106.11.875.875

Published: 2005

Journal Articles

Thrombotic and Hemorrhagic Events for Patients on Pediatric Oncology Group (POG) Protocols 9201, 9605, 9406.

Megan A. Rice, Beverly A. Bell, MD, Allen Chauvenet, MD, Joanne Kurtzberg, MD, Sharon B. Abish, MD, Jeanette Pullen, MD, Meenakshi Devidas, PhD, Bruce M. Camitta, MD

Blood (2005) 106 (11): 880.

https://doi.org/10.1182/blood.V106.11.880.880

Published: 2005

Journal Articles

A Report of the Event-Free Survival (EFS) and Neurotoxicity for Children with Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia (ALL) on Pediatric Oncology Group (POG) Protocol 9405.

Stephen Rodes, BS, Beverly A. Bell, MD, Sharon B. Abish, MD, Jeanette Pullen, MD, Allen Chauvenet, MD, Joanne Kurtzberg, MD, Meenakshi Devidas, PhD, Jonathan Shuster, PhD, Bruce M. Camitta, MD

Blood (2005) 106 (11): 882.

https://doi.org/10.1182/blood.V106.11.882.882

Published: 2005

Journal Articles

Prognostic Significance of Minimal Residual Disease (MRD) in Children with High Risk Acute Lymphoblastic Leukemia(ALL) A Children’s Oncology Group Study.

Michael J. Borowitz, MD, PhD, Meenakshi Devidas, PhD, W. Paul Bowman, MD, Eric Larsen, MD, Jeanette Pullen, MD, Bruce Camitta, MD

Blood (2005) 106 (11): 85.

https://doi.org/10.1182/blood.V106.11.85.85

Published: 2005

Journal Articles

Perforin Polymorphism A91V and Susceptibility to Childhood Acute Lymphoblastic Leukemia (ALL).

Parinda A. Mehta, MD, Stella M. Davies, MBBS, Ashish Kumar, MD, Meenakshi Devidas, PhD, Susan Lee, BS, Tiffany Wilke, BS, James Elliott, BS, MBA, Joyce Villanueva, BS, Jeanette Pullen, MD, Yetnayet Zewge, Alexandra H. Filipovich, MD

Blood (2005) 106 (11): 1453.

https://doi.org/10.1182/blood.V106.11.1453.1453

Published: 2005

Journal Articles

Comparison of Diagnostic and Relapse Flow Cytometry Phenotypes in Childhood ALL: Implications for Residual Disease (MRD) Detection.

Michael J. Borowitz, MD PhD, D. Jeanette Pullen, MD, Naomi Winick, MD, P. L. Martin, MD, W. Paul Bowman, MD, Bruce Camitta, MD

Blood (2004) 104 (11): 1091.

https://doi.org/10.1182/blood.V104.11.1091.1091

Published: 2004

Journal Articles

Biology-Driven Classification of Childhood Acute Lymphoblastic Leukemia: A Combined Analysis of Prognostic Markers from the Pediatric Oncology Group (POG) and Children’s Cancer Group (CCG).

Kirk R. Schultz, MD, Jeanette Pullen, MD, Harland Sather, PhD, Jonathan Shuster, PhD, Michael J. Borowitz, MD, Nyla A. Heerema, PhD, Andrew J. Carroll, PhD, Paul S. Gaynon, MD, Bruce M. Camitta, MD

Blood (2004) 104 (11): 519.

https://doi.org/10.1182/blood.V104.11.519.519

Published: 2004

NARROW

Molecular Basis Of Minimal Residual Disease In Subtypes Of Pediatric B Cell Acute Lymphoblastic Leukemia

Delayed Intensification (DI) Enhances Event-Free Survival (EFS) of Children with B-Precursor Acute Lymphoblastic Leukemia (ALL) Who Received Intensification Therapy with Six Courses of Intravenous Methotrexate (MTX): POG 9904/9905: A Childrens Oncology Group Study (COG).

Prospective Analysis of TEL and MLL Gene Rearrangements in Childhood Acute Lymphoblastic Leukemia: A Children’s Oncology Group Study.

Prognostic Significance of Minimal Residual Disease (MRD) in Childhood B-Precursor ALL and Its Relation to Other Risk Factors. A Children’s Oncology Group (COG) Study.

A Report of the Event Free Survival (EFS) for Children with Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia (ALL) Treated on Pediatric Oncology Group (POG) Protocol 9605.

Thrombotic and Hemorrhagic Events for Patients on Pediatric Oncology Group (POG) Protocols 9201, 9605, 9406.

A Report of the Event-Free Survival (EFS) and Neurotoxicity for Children with Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia (ALL) on Pediatric Oncology Group (POG) Protocol 9405.

Prognostic Significance of Minimal Residual Disease (MRD) in Children with High Risk Acute Lymphoblastic Leukemia(ALL) A Children’s Oncology Group Study.

Perforin Polymorphism A91V and Susceptibility to Childhood Acute Lymphoblastic Leukemia (ALL).

Comparison of Diagnostic and Relapse Flow Cytometry Phenotypes in Childhood ALL: Implications for Residual Disease (MRD) Detection.

Biology-Driven Classification of Childhood Acute Lymphoblastic Leukemia: A Combined Analysis of Prognostic Markers from the Pediatric Oncology Group (POG) and Children’s Cancer Group (CCG).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only